NSCLC: Study Assesses Adjuvant Chemo Decision-making Role Preferences

NSCLC: Study Assesses Adjuvant Chemo Decision-making Role Preferences
NSCLC: Study Assesses Adjuvant Chemo Decision-making Role Preferences

Most patients with resected non-small cell lung cancer (NSCLC) preferred a collaborative role in decision-making about adjuvant chemotherapy, a study published in the journal Lung Cancer has shown.1

Because patients with cancer have differing preferences for involvement in decision-making, researchers sought to determine the preferred and perceived involvement in decision-making among patients considering adjuvant chemotherapy following resection of early NSCLC.

For the study, researchers enrolled 98 patients to complete a self-administered questionnaire assessing preferred and perceived decision-making role at baseline and 6 months. Of those, 75 completed the 6-month questionnaire.

Continue Reading Below

Results showed that the preferred role in decision-making at baseline was active in 27%, collaborative in 47%, and passive in 27% of the 98 patients; however, perceived decision-making roles only matched the preferred role in 79% of patients.

Researchers also found that preferring an active role was associated with university education (OR, 2.9; P=.02), opting to forego adjuvant chemotherapy (OR, 5.0; P<.01), and worse health-related quality of life during adjuvant chemotherapy.

The study also demonstrated that patients who preferred an active decision-making role felt that a larger survival benefit was necessary to make adjuvant chemotherapy worthwhile compared with those who preferred a passive role. Specifically, physical well-being (OR, 4.4; P=.05), overall well-being (OR, 5.5; P=.02), sleep (OR, 8.4; P<.01), and shortness of breath (OR, 7.6; P=.01) were linked with preferring a more active role.

“Clinicians should elicit and consider patients' preferences for involvement in decision-making when discussing [adjuvant chemotherapy] for NSCLC,” the authors conclude.

Continue Reading Below

REFERENCE

1. Moth E, McLachlan SA, Veillard AS, et al. Patients' preferred and perceived roles in making decisions about adjuvant chemotherapy for non-small-cell lung cancer [published online ahead of print February 20, 2016]. Lung Cancer. doi:10.1016/j.lungcan.2016.02.009.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs